Group One Trading, L.P. Humanigen, Inc Transaction History

Group One Trading, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.12 - $0.23 $180 - $345	-1,502 Reduced 5.41%	26,265 $3,000
Q4 2022 Feb 09, 2023	SELL	$0.09 - $0.2 $2,664 - $5,920	-29,600 Reduced 51.6%	27,767 $3,000
Q3 2022 Nov 09, 2022	BUY	$0.15 - $3.02 $4,768 - $96,011	31,792 Added 124.31%	57,367 $10,000
Q2 2022 Aug 11, 2022	SELL	$1.76 - $3.33 $649,971 - $1.23 Million	-369,302 Reduced 93.52%	25,575 $45,000
Q1 2022 May 12, 2022	BUY	$1.81 - $3.97 $371,200 - $814,179	205,083 Added 108.06%	394,877 $1.19 Million
Q4 2021 Feb 11, 2022	SELL	$3.66 - $8.22 $30,304 - $68,061	-8,280 Reduced 4.18%	189,794 $706,000
Q3 2021 Nov 12, 2021	BUY	$5.93 - $17.83 $244,203 - $734,257	41,181 Added 26.25%	198,074 $1.18 Million
Q2 2021 Aug 10, 2021	BUY	$13.54 - $22.74 $1.34 Million - $2.25 Million	98,859 Added 170.35%	156,893 $2.73 Million
Q1 2021 May 12, 2021	BUY	$12.91 - $23.83 $737,406 - $1.36 Million	57,119 Added 6242.51%	58,034 $1.11 Million
Q4 2020 Feb 10, 2021	BUY	$7.97 - $21.66 $7,292 - $19,818	915 New	915 $16,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.